Bullish & Foolish
Full RNTX fundamentals All 466 on the Survival Watch

RNTXRein Therapeutics, Inc.

Is Rein Therapeutics struggling financially?

Yes, by its own account. Rein Therapeutics told the SEC on 8 Jun 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Jun 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$70.6M
Source filing
DEF 14A 8 Jun 2026
Balance sheet
30 Jun 2026

Cash runway

  • 11months

    If the burn speeds up

    Empty by May 2027

  • 17months

    If it eases off

    Empty by Nov 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$40.6M

÷

Cash burned over the last 12 months

$34.8M

What Rein Therapeutics told the SEC

…not qualified or modified as to uncertainty, audit scope, or accounting principles. The report included an explanatory paragraph indicating that there was substantial doubt about the Company’s ability to continue as a going concern. During the year ended December 31, 2024 and through April 16, 2025, the date of resignation, there were (i) no “disagreements”, as that term is defined in Item 304(a)(1)(iv) of…

Rein Therapeutics, Inc., Form DEF 14A, filed 8 Jun 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 111.7% share-count increase The company issued stock. Each share now owns 52.8% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt